Kira Pharmaceuticals to Present New Preclinical Data on Lead Asset KP104 at the 2022 European Meeting on Complement in Human Disease Conference
/PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, will...
Source: prnewswire.com